Form 4: Alphatec CFO Awarded Over 446K RSUs, Forfeits Some

Alphatec Holdings' CFO, John Todd Koning, received significant RSU awards tied to performance and time, while also forfeiting a portion of previous awards.

Summary

• Alphatec Holdings, Inc. CFO, John Todd Koning, was awarded a total of 446,262 Restricted Stock Units (RSUs) on February 25, 2026.
• This includes 205,094 performance-based RSUs for satisfying FY2025 criteria, vesting in three equal installments starting March 5, 2026.
• An additional 110,394 time-based RSUs were awarded, vesting in three equal installments starting March 5, 2027.
• Koning also received 20,380 RSUs in lieu of a portion of his 2025 cash bonus, vesting on December 4, 2026.
• Two separate awards of up to 55,197 performance-based RSUs each (totaling 110,394 derivative RSUs) were granted, tied to stock price targets ($25.00 by Dec 31, 2028; $36.00 by Dec 31, 2030) and operational metrics.
• Beneficial ownership of non-derivative common stock following these transactions is 749,420 shares, and 110,394 derivative RSUs.
• Koning forfeited 32,403 previously reported RSUs due to not meeting applicable performance criteria.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development. While there was a forfeiture of some RSUs, the significant new awards, especially those tied to ambitious stock price targets, signal management's confidence and a strong incentive structure for future growth.

Positives

• Significant RSU awards totaling 446,262 units demonstrate continued commitment to executive compensation aligned with company performance and retention.
• The performance-based RSU awards, tied to stock price targets ($25.00 and $36.00 per share) and operational metrics, incentivize the CFO to drive long-term shareholder value and operational excellence.
• The grant of 20,380 RSUs in lieu of a cash bonus indicates a preference for equity-based compensation, further aligning management's interests with shareholders.

Negatives

• The forfeiture of 32,403 previously reported RSUs indicates that certain performance criteria were not met, which could suggest underperformance in specific areas.

Risks

• The performance-based RSUs are contingent on achieving specific stock price targets ($25.00 by December 31, 2028, and $36.00 by December 31, 2030) and operational metrics, meaning the full value of these awards is not guaranteed and depends on future company performance and market conditions.
• Failure to meet future performance criteria could lead to further forfeiture of unvested RSUs, impacting executive compensation and potentially signaling ongoing challenges.

Future Outlook

The filing indicates a forward-looking compensation strategy for the CFO, with significant RSU awards tied to future stock price performance targets of $25.00 by December 31, 2028, and $36.00 by December 31, 2030, as well as the achievement of certain operational metrics by December 31, 2028, and December 31, 2030. These targets suggest management's expectations for substantial growth in shareholder value and operational success over the next several years.

Industry Context

StockSavvy.ai notes that the use of performance-based Restricted Stock Units (RSUs) with specific stock price and operational targets is a common practice in the medical technology and spine device industry. This approach aligns executive incentives with long-term shareholder value creation, a critical factor in a sector characterized by innovation, regulatory hurdles, and competitive pressures. Companies like Medtronic (MDT) and Stryker (SYK) also frequently utilize similar equity-based compensation structures to motivate leadership and retain talent, especially in roles crucial for financial oversight and strategic execution like the CFO.

Comparison to Industry Standards

• The RSU awards, particularly those tied to stock price performance targets of $25.00 and $36.00, are aggressive yet common in growth-oriented medical device companies. For instance, a comparable company like NuVasive (acquired by Globus Medical, GMED) often set ambitious equity targets for its executives during its growth phase, reflecting confidence in future market penetration and product success.
• The mix of performance-based, time-based, and bonus-in-lieu RSUs is a standard diversified compensation package designed for both retention and performance incentives, similar to practices observed at larger industry players such as Zimmer Biomet (ZBH) and DePuy Synthes (a Johnson & Johnson company).
• The forfeiture of 32,403 RSUs due to unmet performance criteria underscores the rigor of Alphatec's compensation committee, aligning with best practices in corporate governance where executive pay is genuinely at risk based on results, a standard upheld by institutional investors across the healthcare sector.

Corporate Governance

Stakeholder Impact

• Shareholders: The RSU awards, particularly those tied to stock price performance, align the CFO's interests with shareholders, potentially driving efforts to increase share value. The forfeiture of RSUs for unmet criteria demonstrates accountability.
• Employees: The compensation structure for a key executive like the CFO can set a precedent or reflect the company's overall approach to performance-based incentives, potentially influencing broader employee motivation and retention strategies.

Next Steps

• Achievement of stock price targets of $25.00 per share by December 31, 2028, and $36.00 per share by December 31, 2030, for vesting of performance-based RSUs.
• Achievement of certain operational metrics by December 31, 2028, and December 31, 2030, for vesting of performance-based RSUs.
• Vesting of 205,094 performance-based RSUs in three equal installments on March 5, 2026, March 5, 2027, and March 5, 2028.
• Vesting of 110,394 time-based RSUs in three equal installments on March 5, 2027, March 5, 2028, and March 5, 2029.
• Vesting of 20,380 bonus-in-lieu RSUs on December 4, 2026.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation awards and a minor forfeiture, which are generally expected events for a publicly traded company. While the performance-based RSUs signal management's confidence in future growth and align incentives, the forfeiture indicates that not all prior targets were met. These transactions do not present new material information that would significantly alter the fundamental investment thesis for Alphatec Holdings, Inc. Therefore, a 'hold' recommendation is appropriate, suggesting investors maintain their current position while monitoring future operational and financial performance.

Keywords

Alphatec Holdings, ATEC, Form 4, SEC filing, Restricted Stock Units, RSUs, executive compensation, insider ownership, CFO, performance-based awards, stock awards, corporate governance